The role of i.v. ibandronate administration in osteoporosis therapy

Endokrynologia Polska

Volumn 62, Issue 1, 2011, Pages 51-60

  Sewerynek, Ewa ^a   Stuss, Michał ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

Ibandronate; Intravenous; Osteoporosis

Indexed keywords

ALENDRONIC ACID; ALFACALCIDOL; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; CLODRONIC ACID; COLECALCIFEROL; CORTICOSTEROID; ETIDRONIC ACID; IBANDRONIC ACID; OSTEOCALCIN; PAMIDRONIC ACID; PLACEBO; PREDNISONE; RISEDRONIC ACID; TILUDRONIC ACID; ZOLEDRONIC ACID;

ACUTE KIDNEY FAILURE; ADVERSE OUTCOME; ARTHRALGIA; ASTHENIA; BACKACHE; BONE; BONE BIOPSY; BONE DENSITY; BONE METASTASIS; BONE MINERAL; BONE TURNOVER; BREAST CARCINOMA; CATARACT; CHRONIC DISEASE; CORTICOSTEROID INDUCED OSTEOPOROSIS; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG FATALITY; DRUG INDICATION; DRUG INTERMITTENT THERAPY; DRUG MECHANISM; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMUR NECK; FLU LIKE SYNDROME; FRACTURE; GASTROINTESTINAL DISEASE; GASTROINTESTINAL SYMPTOM; HEADACHE; HEART ATRIUM FIBRILLATION; HIP FRACTURE; HUMAN; HYPERCALCEMIA; HYPERTENSION; HYPOGONADISM; INJECTION SITE REACTION; JAW OSTEONECROSIS; LARYNGEAL TUBERCULOSIS; LIMB PAIN; LUMBAR SPINE; MULTIPLE MYELOMA; MYALGIA; NEPHROTOXICITY; NONHUMAN; OSTEOPOROSIS; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; POSTMENOPAUSE OSTEOPOROSIS; REVIEW; RHINOPHARYNGITIS; RISK REDUCTION; SINGLE DRUG DOSE; SINUSITIS; SKIN DISEASE; STROKE; TREATMENT OUTCOME; VERTEBRA FRACTURE;

EID: 79953828935     PISSN: 0423104X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (64)

1. Kanis JA, McCloskey EV, Johansson H et al. Development and use of FRAX in osteoporosis. Osteoporos Int 2010; 21 (Suppl. 2): S407-413.
2. Kanis JA, Johnell O, Oden A et al. FRAX™ and the assessment of fracture probability in men and women from the UK. Osteoporos Int 2008; 19: 385-397.
3. Nguyen ND, Frost SA, Center JR et al. Development of prognostic nomograms for individualizing 5-year and 10-year fracture risks. Osteoporos Int 2008; 19: 1431-1444.
4. Pluskiewicz W, Adamczyk P, Franek E et al. Ten-year probability of osteoporotic fracture in 2012 Polish women assessed by FRAX and nomogram by Nguyen et al. Conformity between methods and their clinical utility. Bone 2010; 46: 1661-1667.
5. Franek E, Wichrowska H, Gozdowski D et al. WHO fracture risk calculator (FRAX) in the assessment of obese patients with osteoporosis. Endokrynol Pol (Pol J Endocrinol) 2009; 60: 82-87.
6. Pols HA, Felsenberg D, Hanley D.A et al. Multinational, placebo-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: results of the FOSIT study. Osteoporos Int 1999; 9: 461-468. (Pubitemid 29231740)
7. Black DM, Tompson DE, Bajer DC et al. For FIT Research Group. Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. J Clin Endocrinol Metab 2000; 85: 4118-4124. (Pubitemid 32055362)
8. Cranney A, Wells G, Wilian A et al. Meta-analysis of alendronate for the treatment of postmenopausal women. Endocrine Res 2002; 23: 508-516. (Pubitemid 34925644)
9. Chesnut III CH, McClung MR, Ensrud K et al. Alendronate treatment of the postmenopausal osteoporotic woman: Effect of multiple dosages on bone mass and bone remodeling. Am J Med. 1995; 99: 144-152.
10. Orwoll E, Ettinger M, Weiss S et al. Alendronate for the treatment of osteoporosis in men. N Engl J Med 2000; 343: 604-610.
11. Adachi JD, Saag KG, Delmas PD et al. Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: a randomized, double-blind, placebo-controlled trail. Arthritis Rheum 2001; 44: 202-211. (Pubitemid 32113136)
12. Schnitzer T, Bone HG, Crepaldi G et al. Therapeutic equivalence of alendronate 70 mg once weekly and alendronate 10 mg daily in the treatment of osteoporosis. Alendronate Once-Weekly Study Group. Aging 2000; 12: 1-12. (Pubitemid 30136655)
13. Rosen CJ, HochbergMC, Bonnick SL et al. Treatment with once-weekly alendronate 70 mg compared with once-weekly risendronate 35 mg in women with postmenopausal: a randomized double-blind study. J Bone Miner Res 2005; 20: 141-151. (Pubitemid 41716229)
14. Fleisch H. Bisphosphonates: mechanisms of action. Endocr Rev 1998; 19: 80-100. (Pubitemid 29122075)
15. Sewerynek E, Stuss M. Bisphosphonates and the risk of atrial fibrillation. Endokrynol Pol 2011; 62: 107-110.
16. Frith JC, Monkkonen J, Blackburn GM et al. Clodronate and liposome-encapsulated clodronate are metabolized to a toxic ATP analog, adenosine 5′-(â, ā-dichloromethylene) triphosphate, by mammalian cells in vitro. J Bone Min Res 1997; 12: 1358-1367. (Pubitemid 27375378)
17. Lehenkari PP, Kellinsalmi M, Napankangas JP et al. Further insight into mechanism of action of clodronate: inhibition of mitochondrial ADP/ATP translocase by a non-hydrolyzable, adenine-containing metabolite. Mol Pharmacol 2002; 61: 1255-1262. (Pubitemid 34441791)
18. Fujikawa Y, Sabokbar A, Neale SD et al. The effect of macrophage-colony stimulating factor and other humoral factors (interleukin-1, -3, -6, and -11, tumor necrosis factor-â, and granulocyte macrophage-colony stimulating factor) on human osteoclast formation from circulating cells. Bone 2001; 28: 261-267. (Pubitemid 32194418)
19. Chesnut III CH, Skag A, Christiansen C et al. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 2004; 19: 1241-1249. (Pubitemid 41094364)
20. Reginster JY, Adami S, Lakatos P et al. Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2 year results from the MOBILE study. Ann Rheum Dis 2006; 65: 654-661.
21. Orwoll ES, Binkley NC, Lewiecki EM et al. Efficacy and safety of monthly ibandronate in men with low bone density. Bone 2010; 46: 970-976.
22. Emkey R, Koltun W, Beusterien K et al. Patient preference for once-monthly ibandronate versus once-weekly alendronate in a randomized, open-label, cross-over trial: the Bonviva Alendronate Trial in Osteoporosis (BALTO). Curr Med Res Opin 2005; 21: 1895-903. (Pubitemid 41803098)
23. Cooper A, Drake J, Brankin E et al. Treatment persistence with one-monthly ibandronate and patients support vs once-weekly alendronate: results from the PERSIST study. Int J Clin Pract 2006; 60: 896-905. (Pubitemid 44082279)
24. Derman R, Sydney LB, Kohles J et al. Improved satisfaction with monthly ibandronate in women previously receiving weekly bisphosphonates. Obstet Gynecol 2007; 109 (Suppl. 4): 111-112S.
25. Lewiecki EM, Babbitt AM, Piziak VK et al. Adherence to and gastrointestinal tolerability of monthly oral or quarterly intravenous ibandronate therapy in women with previous intolerance to oral bisphosphonates: a 12-month, open-label, prospective evaluation. Clin Ther 2008; 30: 605-621. (Pubitemid 351680495)
26. Emkey R, Delmas PD, Bolognese M et al. Efficacy and tolerability of once-monthly oral ibandronate (150 mg) and once-weekly oral alendronate (70 mg): additional results from the Monthly Oral Therapy With Ibandronate For Osteoporosis Intervention (MOTION) study. Clin Ther 2009; 31: 751-761.
27. Miller PD, Epstein S, Sedarati F et al.Once-monthly oral ibandronate compared with weekly oral alendronate in postmenopausal osteoporosis: results from the head-to-head MOTION study. Curr Med Res Opin 2008; 24: 207-213. (Pubitemid 351160253)
28. Bounameaux HM, Schifferli J, Montani JP et al. 1983. Renal failure associated with intravenous diphosphonates. Lancet 1983; 1: 471. (Pubitemid 13137388)
29. Dumon JC, Magritte A, Body JJ. Efficacy and safety of the bisphosphonate tiludronate for the treatment of tumor-associated hypercalcemia. Bone Miner 1991; 15: 257-266.
30. O'Sullivan TL, Akbari A, Cadnapaphornchai P. Acute renal failure associated with the administration of parenteral etidronate. Ren Fall 1994; 16: 767-773. (Pubitemid 24378932)
31. Pfister T, Atzpodien E, Bauss F. The renal effects of minimally nephrotoxic doses of ibandronate and zoledronate following single and intermittent intravenous administration in rats. Toxicology 2003; 191: 159-167. (Pubitemid 37329461)
32. Pecherstorfer M, Steinhauer EU, Rizzoli R et al. Efficacy and safety of ibandronate in the treatment of hypercalcemia of malignancy: a randomized multicentric comparison to Pamidronate. Suppor Care Cancer 2003; 11: 539-547. (Pubitemid 36994438)
33. Body JJ, Diel IJ, Lichinitser MR et al. Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases. Ann Oncol 2003; 14: 1399-1405. (Pubitemid 37185286)
34. Body JJ, Diel IJ, Tripathy D et al. Intravenous ibandronate does not affect time to renal function deterioration in patients with skeletal metastases from breast cancer: phase III trial results. Eur J Cancer Care 2006; 15: 299-302. (Pubitemid 44050703)
35. Lyubimova NV, Kushlinsky NE, Lichinitser M. Long-term treatment with intravenous ibandronate does not effect renal function in breast cancer patients with metastatic bone disease. Support Care Cancer 2003; 11: 416 (abstract A-107].
36. Pecherstorfer M, Diel IJ. Rapid administration of ibandronate does not affect renal functioning: evidence from clinical studies in metastatic bone disease and hypercalcaemia of malignancy. Support Care Cancer 2004; 12: 877-881. (Pubitemid 40104784)
37. Body JJ, Lichinitser M, Andreeva N et al. Safety of an intravenous (i.v.) dose of ibandronate followed by daily oral dosing in metastatic bone disease: Results of an open-label study. J Clin Oncol 2004; 22: 60S.
38. Neugebauer G, Koehler W, Akinkunmi L et al. Influence of peak ibandronic acid concentrations after 6 mg i.v. administration with shortened infusion time (15 and 30 minutes) on renal safety in man. Proc Am Soc Clin Oncol 2001; 20: 122A [abstract 486].
39. Thiébaud D, Burckhardt P, Kriegbaum H et al. Three monthly intravenous injections of ibandronate in the treatment of postmenopausal osteoporosis. Am J Med 1997; 103: 298-307. (Pubitemid 27459256)
40. Recker RR, Stakkestad J, Chesnut C et al. Insufficiently dosed intravenous ibandronate injections are associated with suboptimal antifracture efficacy in postmenopausal osteoporosis. Bone 2004; 34: 890-899. (Pubitemid 38581135)
41. Adami S, Felsenberg D, Christiansen C et al. Efficacy and safety of ibandronate given by intravenous injection once every 3 months. Bone 2004; 34: 881-889. (Pubitemid 38581134)
42. Stakkestad JA, Benevolenskaya LJ, Stepan JJ et al. Intravenous ibandronate injections given every three months: a new treatment option to prevent bone loss in postmenopausal women. Ann Rheum Dis 2003; 62: 969-975. (Pubitemid 37159496)
43. Ringe JD, Dorst A, Faber H et al. Intermittent intravenous ibandronate injections reduce vertebral fracture risk in corticosteroid-induced osteoporosis: results from a long-term comparative study. Osteoporos Int 2003; 14: 801-807. (Pubitemid 37462129)
44. Christiansen C, Tanko LB, Warming L et al. Dose dependent effects on bone resorption and formation of intermittently administered intravenous ibandronate. Osteoporos Int 2003; 14: 609-613. (Pubitemid 36975561)
45. Eisman JA, Civitelli R, Adami S et al. Efficacy and tolerability of intravenous ibandronate injections in postmenopausal osteoporosis: 2-year results from DIVA Study. J Rheumatol 2008; 35: 488-497. (Pubitemid 351374427)
46. Recker EE, Ste-Marie LG, Langdahl B et al. Effects of intermittent intravenous ibandronate injections on bone quality and micro-architecture in women with postmenopausal osteoporosis: the DIVA study. Bone 2010; 46: 660-665.
47. Sambrook P, Cranney A, Adachi JD. Risk reduction of non-vertebral fractures with intravenous ibandronate: post-hoc analysis from DIVA. Curr Med Res Opin 2010; 26: 599-604.
48. Harris ST, Blumentals WA, Miller PD. Ibandronate and the risk of non-vertebral and clinical fractures in women with postmenopausal osteoporosis: results of a meta-analysis of phase III studies. Curr Med Res Opin 2008; 24: 237-245. (Pubitemid 351160255)
49. Lamy O, Sandini L, Pache I et al. Intravenous ibandronate in men with osteoporosis: An open pilot study over 2 years. J Endocrinol Invest 2003; 26: 728-732. (Pubitemid 37441501)
50. Kaemmerer D, Lehmann G, Wolf G et al. Treatment of osteoporosis after liver transplantation with ibandronate. Transpl Int 2010; 23: 753-759.
51. Fahrleitner-Pammer A, Piswanger-Soelkner JC, Pieber TR et al. Ibandronate prevents bone loss and reduces vertebral fracture risk in male cardiac transplant patients: a randomized double-blind, placebo-controlled trial. J Bone Miner Res 2009; 24: 1335-1344.
52. Abu-ID M, Warnke PH, Gottschalk J et al. "Bis-phossy jaws" - high and low risk factors for bisphosphonate-induced osteonecrosis of the jaw. J Cran-Maxillofac Surg 2008; 36: 95-103.
53. Woo SB, Hellstein JW, Kalmar JR. Systematic Review: Bisphosphonates and Osteonecrosis of the Jaws. Annals of Internal Med 2006; 144: 753-761.
54. Bhuriya R, Singh M, Molnar J et al. Bisphosphonate use in women and the risk of atrial fibrillation: a systematic review and meta-analysis. Int J Cardiol 2010; 142: 213-217.
55. Mak A, Cheung MW, Ho RC et al. Bisphosphonates and atrial fibrillation: Bayesian meta-analyses of randomized controlled trials and observational studies. BMC Musculoskelet Disord 2009; 10: 113-126.
56. Lewiecki ME, Cooper C, Thompson E. Ibandronate does not increase risk of atrial fibrillation in analysis of pivotal clinical trials. Int J Clin Pract 2010; 64: 821-826.
57. Derman R, Kohles JD, Babbitt A. Gastrointestinal tolerability with ibandronate after previous weekly bisphosphonate treatment. Clin Interv Aging 2009; 4: 357-365.
58. deGroen PC, Lubbe DF, Hirsch LJ et al. Esophagitis associated with the use of alendronate. NEJM 1996; 335: 1016-1021.
59. Ettinger B, Pressman A, Schein J. Clinic visits and hospital admissions for care of acid-related upper gastrointestinal disorders in women using alendronate for osteoporosis. Am J Manag Care 1998; 4: 1377-1382.
60. Graham DY, Malaty HM. Alendronate gastric ulcers. Aliment Pharmacol Ther 1999; 13: 515-419.
61. Lanza FL, Hunt RH, Thomson AB et al. Endoscopic comparison of esophageal and gastroduodenal effects of risedronate and alendronate in postmenopausal women. Gastroenterology 2000; 119: 631-638.
62. Lanza FL, Rack MF, Li Z et al. Placebo-controlled, randomized, evaluator-blinded endoscopy study of risedronate vs aspirin in healthy postmenopausal women. Aliment Pharmacol Ther 2000; 14: 1663-1670.
63. Sewerynek E, Dabrowska K, Skowrońska-Jóźwiak E et al. Compliance with alendronate 10 treatment in elderly women with postmenopausal osteoporosis. Endokrynol Pol 2009; 60: 76-81.
64. Sewerynek E. Wpływ współpracy lekarza z pacjentem na efektywność leczenia osteoporozy. Terapia 2006; 3: 43-46.